A Phase II Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamic (PD) Profile of TQH3906 in Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 12 Oct 2024
At a glance
- Drugs TQH 3906 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical
Most Recent Events
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 12 Aug 2024 New trial record